Alpenglow Biosciences, a Seattle-based biotech startup, recently announced that it secured a $2 million research grant from the National Institute of Health and a $1 million investment to further develop its 3D spatial biology imaging technology platform. In addition, the company’s co-founder, Jonathan Liu, was awarded a contract for up to $21 million to develop technology for precision tumor removal as part of the Biden Administration’s Cancer Moonshot initiative. Alpenglow was originally known as Lightspeed Microscopy and was founded in 2018 by Liu, along with Adam Glaser and Lawrence True, all from the University of Washington.
Led by CEO Nicholas Reder, Alpenglow Biosciences currently has 20 employees and its investors include Alexandria, Dynamk Capital, First In Ventures, Hamamatsu, Mayo Clinic, and WRF Capital. The company specializes in 3D spatial biology imaging technology, which allows for the visualization of biological processes in three dimensions at the cellular level. This technology has a wide range of applications, including precision tumor removal, drug development, and personalized medicine. The recent funding will enable Alpenglow to further develop its platform and expand its capabilities in the field of spatial biology imaging.
The $2 million research grant from the National Institute of Health will support Alpenglow’s ongoing research and development efforts, while the $1 million investment will provide additional capital for the company to scale up its operations. The contract awarded to Jonathan Liu for precision tumor removal technology is a significant milestone for Alpenglow, as it highlights the company’s expertise in developing cutting-edge medical technologies. The Biden Administration’s Cancer Moonshot initiative aims to accelerate cancer research and improve patient outcomes by investing in innovative technologies and treatments.
With its strong team of scientists and researchers, Alpenglow Biosciences is well-positioned to make significant contributions to the field of spatial biology imaging. The company’s focus on developing advanced imaging technologies for biological research and medical applications has attracted the attention of investors and collaborators, including leading healthcare organizations and research institutions. Alpenglow’s innovative approach to studying biological processes in three dimensions has the potential to revolutionize the way we understand and treat various diseases, including cancer.
As Alpenglow Biosciences continues to grow and expand its capabilities, it is poised to become a key player in the field of spatial biology imaging technology. With its recent funding and contract awards, the company is well-equipped to advance its research and develop new applications for its platform. By leveraging its expertise in 3D imaging technology and partnering with industry leaders and research institutions, Alpenglow is paving the way for breakthroughs in precision medicine and personalized healthcare. The company’s commitment to innovation and scientific excellence positions it as a leader in the biotech industry and a key contributor to the ongoing fight against cancer and other complex diseases.
